U.S. Markets close in 2 hrs 32 mins
  • S&P 500

    4,542.47
    -7.31 (-0.16%)
     
  • Dow 30

    35,680.42
    +77.34 (+0.22%)
     
  • Nasdaq

    15,084.06
    -131.64 (-0.87%)
     
  • Russell 2000

    2,288.43
    -7.75 (-0.34%)
     
  • Gold

    1,795.50
    +13.60 (+0.76%)
     
  • EUR/USD

    1.1629
    -0.0001 (-0.0116%)
     
  • 10-Yr Bond

    1.6520
    -0.0240 (-1.43%)
     
  • Vix

    15.55
    +0.54 (+3.60%)
     
  • GBP/USD

    1.3743
    -0.0053 (-0.3834%)
     
  • USD/JPY

    113.5210
    -0.4670 (-0.4097%)
     
  • BTC-USD

    60,947.46
    -2,221.42 (-3.52%)
     
  • CMC Crypto 200

    1,450.76
    -52.27 (-3.48%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,804.85
    +96.27 (+0.34%)
     

Biogen's New Alzheimer's Drug Turned Away By Veterans Affairs

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • The Department of Veterans Affairs (VA) has decided not to include the new Alzheimer's drug developed by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY), Stat News reported citing a notice issued by the federal agency.

  • The department has cited the lack of evidence of "a robust and meaningful clinical benefit" alongside safety concerns.

  • Sales reps will not be allowed to promote the drug to VA doctors, either, another agency document shows.

  • However, the VA unveiled that it would make exceptions for certain patients and announced requirements for the issuance of coverage, such as recent MRI brain scans, mild Alzheimer's, and prescriptions from providers who specialize in the treatment of dementia.

  • The latest hit to the uptake of the drug comes after U.S. Medicare started a review process for national Medicare coverage of Biogen's Aduhelm.

  • Price Action: BIIB shares closed at $339.05 on Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.